Looks like the games over. There's no market for this product. DNDN found out the hard way. Provenge has been available for several years and cannot create a niche for the consumers.
The prostrate cancer immune system seems to be to expensive to draw in most of the people who need it. Unless your wealthy it's not affordable.
ADMP doesn't seem to have much value outside of this tech. Their other drugs and pipeline seem to be not a very high priority or have FDA issues.
News 
Market Data 
Discover 
